既往接受抑郁治疗的早期乳腺癌女性的生存结局:丹麦全国性队列研究
该丹麦全国性登记队列研究纳入1998至2011年确诊的45325例早期乳腺癌女性,其中744例(2%)曾因抑郁住院或门诊就诊,6068例(13%)曾接受抗抑郁药治疗。既往使用抗抑郁药者接受非指南治疗的风险显著升高(OR 1.14,95%CI 1.03-1.27),总生存(HR 1.21,95%CI 1.14-1.28)和乳腺癌特异性生存(HR 1.11,95%CI 1.03-1.20)显著更差;既往因抑郁就诊者风险升高但未达统计学显著。
要点
- 既往使用抗抑郁药的早期乳腺癌患者接受非指南治疗风险升高(OR 1.14,95%CI 1.03-1.27)。
- 既往使用抗抑郁药者总生存(HR 1.21,95%CI 1.14-1.28)和乳腺癌特异性生存(HR 1.11,95%CI 1.03-1.20)显著更差。
- 肿瘤分期未提示既往抑郁治疗者诊断延迟。
核心结论
- 既往接受抑郁治疗的女性构成乳腺癌患者中一个较大的亚组,其接受非指南乳腺癌治疗的风险升高,这可能部分导致总生存和乳腺癌特异性生存更差。
研究设计与样本
- 丹麦全国性登记队列研究,纳入1998至2011年确诊的45325例早期乳腺癌女性。
- 744例(2%)曾因抑郁住院或门诊就诊,6068例(13%)曾接受抗抑郁药治疗。
- 采用多因素logistic回归分析既往抑郁治疗与非指南治疗风险的关联,多因素Cox回归比较总生存、乳腺癌特异性生存及自杀死亡风险。
主要发现
- 肿瘤分期未提示既往抑郁治疗者乳腺癌诊断延迟。
- 既往使用抗抑郁药者接受非指南治疗风险显著升高(OR 1.14,95%CI 1.03-1.27)。
- 既往使用抗抑郁药者总生存显著更差(HR 1.21,95%CI 1.14-1.28),乳腺癌特异性生存显著更差(HR 1.11,95%CI 1.03-1.20)。
- 既往因抑郁住院或门诊就诊者估计风险升高但未达统计学显著。
- 亚组分析中,未接受指示性辅助全身治疗者抑郁与不良生存的关联尤其强。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The aim of this nationwide, register-based cohort study was to determine whether women treated for depression before primary early-stage breast cancer are at increased risk for receiving treatment that is not in accordance with national guidelines and for poorer survival. Material and Methods We identified 45,325 women with early breast cancer diagnosed in Denmark from 1998 to 2011. Of these, 744 women (2%) had had a previous hospital contact (as an inpatient or outpatient) for depression and another 6,068 (13%) had been treated with antidepressants. Associations between previous treatment of depression and risk of receiving nonguideline treatment of breast cancer were assessed in multivariable logistic regression analyses. We compared the overall survival, breast cancer-specific survival, and risk of death by suicide of women who were and were not treated for depression before breast cancer in multivariable Cox regression analyses. Results Tumor stage did not indicate a delay in diagnosis of breast cancer in women previously treated for depression; however, those given antidepressants before breast cancer had a significantly increased risk of receiving nonguideline treatment (odds ratio, 1.14; 95% CI, 1.03 to 1.27) and significantly worse overall survival (hazard ratio, 1.21; 95% CI, 1.14 to 1.28) and breast cancer-specific survival (hazard ratio, 1.11; 95% CI, 1.03 to 1.20). Increased but nonsignificant estimated risks were also found for women with previous hospital contacts for depression. In subgroup analyses, the association of depression with poor survival was particularly strong among women who did not receive the indicated adjuvant systemic therapy. Conclusion Women previously treated for depression constitute a large subgroup of patients with breast cancer who are at risk for receiving nonguideline breast cancer treatment, which probably contributes to poorer overall and breast cancer-specific survival.
引用
- Suppli NP, Johansen C, Kessing LV, et al. Survival After Early-Stage Breast Cancer of Women Previously Treated for Depression: A Nationwide Danish Cohort Study. J Clin Oncol. 2016. PMID: 28095267. doi:10.1200/JCO.2016.68.8358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。